Ocular Therapeutix OCUL Increase (decrease) in contract liabilities and current deferred income

Increase (decrease) in contract liabilities and current deferred income at other companies

EyePoint, Inc. EYPT

$0+100%

Revenue$10.8M+0.8%

Gross profit$9.5M+0.2%

Operating income-$93.3M-46.0%

Net income-$88.6M-38.3%

EPS (diluted)-$0.40-5.3%

Cash & equivalents$666.7M+90.7%

Total debt$79.5M+4.2%

Total equity$581.6M+119%

Total assets$732.5M+80.5%

Operating cash flow-$66.0M-47.7%

CapEx$4.7M+141%

Free cash flow-$70.7M-51.6%

Market cap$2.16B+58.2%

Enterprise value$1.57B+40.8%

P/S41.5×+18.6×

Gross margin87.2%-3.4pp

Operating margin-575.4%+1,233pp

Net margin-558.2%+1,493pp

FCF margin-463%+2,860pp

Return on equity-68.6%+17.0pp

Debt / equity0.1×-0.2×

Current ratio14.8×+4.6×

Reported directly by Ocular Therapeutix in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.

The official record: Ocular Therapeutix’s 10-Q, filed August 5, 2025, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Ocular Therapeutix's increase (decrease) in contract liabilities and current deferred income?: Ocular Therapeutix (OCUL) reported increase (decrease) in contract liabilities and current deferred income of -$64K in Q2 2025.
How has Ocular Therapeutix's increase (decrease) in contract liabilities and current deferred income changed year-over-year?: Ocular Therapeutix's increase (decrease) in contract liabilities and current deferred income decreased by 3.2% year-over-year, from -$62K to -$64K.